Shares of Nutex Health fell over 24% in pre-market trading on March 6, 2026, after the company reported Q4 and FY25 results. Nutex Health disclosed that many out-of-network reimbursement claims it had submitted through the federal Independent Dispute Resolution process were ultimately deemed ineligible. In its earnings release, the company stated that the results included “a one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process.” Nutex also acknowledged that prior results had benefited from “Arbitration revenues of $69.0 million relating to submissions during the third quarter of 2024 that were recorded in the fourth quarter of 2024.” Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.